King’s College London researchers discovered that parts of our DNA once thought to be “junk” can actually help destroy cancer ...
Avacta Therapeutics (AIM: AVCT, ‘Avacta’, ‘the Company’), a clinical stage biopharmaceutical company developing pre|CISION ®, a tumor-activated oncology delivery platform, today announced the ...
A collaborative research group has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering precision immunotherapy approaches in oncology and inflammation & immunology (I&I), today announced it will for the first ...
The presentation will feature the first clinical results for ART6043 from the Phase 1/2a study ( NCT05898399 ), including safety, tolerability, pharmacokinetics, and preliminary efficacy in patients ...
The combination of olaparib and radium-223 improved rPFS in CRPC patients with bone metastases compared to radium-223 alone. The greatest benefit was observed in patients without prior docetaxel ...
With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent cancer and the fifth leading cause of cancer death among men in 2022. Hormone ...
Mucin 16–Directed Therapy in Pediatric Sarcomas: Case Evidence of Ubamatamab Efficacy in Epithelioid Sarcoma and Its Implications for Other Sarcoma Subtypes We conducted a phase I trial of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback